Compounded Tirzepatide: Legal Status, Safety and Cost (2026)
The short answer
Compounded tirzepatide is tirzepatide made by a pharmacy or outsourcing facility rather than Eli Lilly, and it is not FDA-approved: FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. FDA declared the tirzepatide shortage resolved on 19 December 2024, its grace periods for compounders ran out by 19 March 2025, and the Fifth Circuit upheld the decision on 27 August 2026. What remains is narrow: a pharmacy may not regularly compound essentially a copy of the approved drug unless a prescriber documents a significant difference for an identified patient, outsourcing facilities cannot use bulk tirzepatide because it is on neither FDA's shortage list nor its 503B bulks list, and FDA has sent warning letters to telehealth companies over claims that imply compounded products are the same as approved ones. FDA has also reported dosing errors with compounded injectable semaglutide, adverse event reports that may be tied to compounded semaglutide or tirzepatide doses above the label, and, by 31 May 2026, more than 730 adverse event reports on compounded tirzepatide, which it says are likely undercounted.
This page covers what compounded tirzepatide is, where it stands legally after the 2024 shortage decision and the 2026 appeals ruling, what FDA says about safety and dosing errors, what Zepbound costs from Lilly, and how all of that differs from the research-labelled vials sold online. The legal, safety, dosing and brand-price statements come from FDA pages, the Zepbound label, a federal court opinion and Lilly pages that we opened on 31 October 2026; the list is at the end. Research-market prices come from the Bureau's own Vendor Watch data, read the same day. We quote no compounded or telehealth price, because we did not open a live provider page.
What Is Compounded Tirzepatide?
Best vendor for tirzepatide right now: Amino Club
30mg vial, $59.99 per vial ($2.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
Check price at Amino Club Compare all vendors Black FridayCyber Monday 40% off, applied by our link (was 20%) code 100 ends 30 NovTirzepatide is a GIP receptor and GLP-1 receptor agonist. Eli Lilly's two FDA-approved tirzepatide products are Mounjaro (type 2 diabetes, approved May 2022) and Zepbound (obesity and other weight-related conditions, approved November 2023), and the Fifth Circuit's 2026 opinion calls them the only FDA-approved tirzepatide products.
Compounding is, in the court's words, "a process by which a pharmacist or doctor combines, mixes, or alters ingredients to create a medication." It happens outside the FDA approval process. FDA puts the limit plainly: "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." Three different things get called compounded or research tirzepatide:
- 503B outsourcing facilities: FDA's April 2026 notice says they are restricted from compounding with bulk drug substances unless the substance is on the 503B bulks list or the drug is on FDA's shortage list, and that tirzepatide is on neither.
- 503A compounding pharmacies: state-licensed pharmacies that compound for an individual patient on a prescription. They may not compound "regularly or in inordinate amounts" drugs that are "essentially copies of a commercially available drug product", with the exception described in the legal section below.
- Research-labelled vials: vials sold online marked "for research purposes" or "not for human consumption". They are not FDA-approved. FDA says it has warned companies that illegally sold unapproved drugs containing tirzepatide that were falsely labelled this way.
Is Compounded Tirzepatide Legal in 2026?
Only in narrow cases, and no longer because of a shortage. This is the sequence, from FDA's own pages and the court record, all opened on 31 October 2026:
| Date | What happened | Source |
|---|---|---|
| 15 December 2022 | Tirzepatide injection products are first added to FDA's drug shortage list. The Fifth Circuit notes that the law's compounding prohibition is temporarily suspended while a drug is on that list. | FDA order; court opinion |
| 2 October 2024 | FDA determines the tirzepatide shortage is resolved and removes it from the list. It says it confirmed with the manufacturer that its stated product availability and manufacturing capacity can meet present and projected national demand. | FDA notice |
| 7 and 11 October 2024 | The Outsourcing Facilities Association and North American Custom Laboratories (d/b/a Farmakeio Custom Compounding) sue FDA in federal court in Texas (7 October). On 11 October, on FDA's motion, a court order sends the decision back to the agency for reevaluation. | FDA order |
| 19 December 2024 | After reevaluating, FDA issues a new order that the shortage is resolved, which it says revokes and replaces the October decision. FDA says it will not act against compounders for conditions that depend on the shortage listing until 18 February 2025 (503A pharmacies) and 19 March 2025 (503B outsourcing facilities), or the court's preliminary injunction ruling if later. | FDA order; FDA notice |
| 5 March 2025 | The district court denies the compounders' request for a preliminary injunction (4:24-cv-00953, N.D. Tex.). FDA says the pharmacy grace period "has ended" and the outsourcing facility period runs to 19 March 2025. | FDA notice |
| 9 September 2025 | FDA warning letter to a telehealth company: a claim on its site implied that its compounded semaglutide and tirzepatide were the same as an FDA-approved product, which FDA called false or misleading. | FDA warning letter |
| 3 March 2026 | FDA announces 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. It calls them the second group since it launched a crackdown on misleading direct-to-consumer drug advertising in September 2025. | FDA news release |
| 1 April 2026 | FDA reminds compounders of the 503A and 503B conditions and states that tirzepatide and semaglutide are not on the 503B bulks list or the shortage list. | FDA notice |
| 27 August 2026 | The Fifth Circuit affirms the judgment for FDA and Eli Lilly (No. 25-10600). | Court opinion |
What pharmacies (section 503A) can still do
FDA's 1 April 2026 notice sets the conditions. A compounded drug must be made for an individual patient on a prescription, and the compounder must not compound, "regularly or in inordinate amounts", drugs that are "essentially copies of a commercially available drug product". FDA says it intends to consider a compounded product essentially a copy when it has the same active ingredient in the same, similar or easily substitutable strength and can be used by the same route, unless "a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient." FDA adds that, "at this time", it does not intend to act against a compounder that fills four or fewer prescriptions of such a copy in a calendar month.
What outsourcing facilities (section 503B) can do
The same notice says outsourcing facilities cannot compound from bulk drug substances unless the substance is on the 503B bulks list or the drug is on FDA's shortage list at the time. It then states: "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list."
What the court decided
The compounders appealed the district court's judgment, and the Fifth Circuit decided the appeal on 27 August 2026. A three-judge panel, in an opinion not designated for publication, affirmed the district court's judgment for FDA and Eli Lilly. It assumed without deciding that FDA should have used notice-and-comment rulemaking, held that the compounders had not shown they were harmed by that, and concluded that FDA's shortage determination "was not arbitrary or capricious." The court described the effect of the October 2024 removal as making it "unlawful for physicians, pharmacies, and outsourcing facilities to compound tirzepatide-injection products"; FDA's conditions above are the more precise statement of what remains.
What FDA has said about marketing
FDA has also gone after how compounded GLP-1s are sold. Its 3 March 2026 announcement covered 30 warning letters to telehealth companies, the second group since FDA launched its September 2025 crackdown on misleading direct-to-consumer drug advertising, and named two main violations: "claims implying sameness with FDA-approved products" and advertising products under the telehealth firm's own brand in a way that implies it is the compounder. FDA's guidance for telehealth companies (current as of 15 June 2026) also lists as misleading any description of a compounded drug as a generic or as "clinically proven to produce the same result as the FDA-approved drug", and any claim that it comes from an FDA-approved or FDA-licensed facility, because "FDA does not approve or license any facility."
Research-labelled vials
FDA says it "has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled 'for research purposes' or 'not for human consumption.'" It notes that these products "have been sold directly to consumers for human use with dosing instructions" and urges consumers not to buy them. The Bureau still reports what this market charges (see the cost section), but a "research use only" label does not turn a vial into an FDA-reviewed drug.
A separate action: on 30 October 2026 HHS published in the Federal Register an interim policy on 503A compounding of six peptides (91 FR 68526), under the same regulatory identifier as the FDA item that cleared White House review on 27 October. Its list is BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, so it does not cover tirzepatide. The details are in our explainer of the published policy and the earlier record in the interim access policy explainer; the wider state-by-state picture is in the research peptides legal status guide.
Is Compounded Tirzepatide Safe?
FDA's position is that it cannot say, because it does not review compounded drugs before they are marketed. What FDA does publish is what has gone wrong (its page is current as of 1 October 2026):
- Adverse event reports. As of 31 May 2026 FDA had received "more than 730 reports of adverse events associated with compounded tirzepatide" and 990 for compounded semaglutide. Federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events, so FDA says "it is likely that adverse events from compounded versions of these drugs are underreported." It also says many of the events "appear to be consistent with adverse events related to the FDA-approved versions", and that it is not always possible to tell whether the drug caused an event.
- Dosing errors. FDA received "multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors" with compounded injectable semaglutide. The errors "resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses." Separately, it received reports tied to patients prescribed compounded semaglutide or tirzepatide "in doses beyond what is in the FDA-approved drug label", including nausea, vomiting, diarrhea, abdominal pain and constipation.
- Multi-dose vials. FDA recommends discarding a multi-dose vial within 28 days after first use, "even if medication remains in the vial", and using a new sterile needle and syringe for each dose.
- Shipping. FDA has received complaints that some compounded GLP-1 drugs "arrived warm or with inadequate ice packs", and recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration.
- Fakes. FDA is aware of fraudulent compounded semaglutide and tirzepatide with false label information; in some cases the pharmacies named on the labels do not exist.
FDA's own red flags for buyers include a company that claims the compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, no screening and prescription from a licensed doctor, and medicine that looks different from what was pictured. FDA recommends that compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug", and that patients get a prescription and fill it at a state-licensed pharmacy. Problems can be reported to FDA's MedWatch program.
Compounded Tirzepatide vs Mounjaro and Zepbound: What Is and Is Not the Same
| Factor | Mounjaro / Zepbound (Lilly) | Compounded (pharmacy or outsourcing facility) | "Research" vial |
|---|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide (FDA's "essentially a copy" test starts from the same active ingredient) | Sold as tirzepatide |
| FDA-approved | Yes (Mounjaro May 2022, Zepbound November 2023) | No | No |
| FDA review of safety, effectiveness and quality before sale | Yes, as part of approval | No, per FDA | No. FDA has warned companies selling unapproved tirzepatide labelled for research |
| Legal route | Prescription. Zepbound vials are sold only through LillyDirect self-pay | Narrow, see the legal section above | FDA says it has warned companies that illegally sold unapproved drugs labelled this way |
| Price, checked 31 October 2026 | Vials $299 to $449 a month self-pay | No verified price, none quoted | 30 mg vials listed at $60.00 to $149.99 (Vendor Watch, before any code) |
The molecule has the same name in all three columns. The assurance does not. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, so what is in a compounded or research-labelled vial depends on the maker and the paperwork behind it. For the brand drug in detail, see the Zepbound guide.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesGet the Dispatch
One research note, one vendor deal, once a week. Free dosing guide on confirm.
Double opt-in. Unsubscribe with one click. Research use only.
How Much Does Compounded Tirzepatide Cost?
We have not opened a live compounding-provider price page today, so this page quotes no compounded price. FDA's stated position is that compounded drugs should only be used in patients whose medical needs an FDA-approved drug cannot meet, which is a separate question from price. Two sets of prices we can source are below.
Zepbound single-dose vials, self-pay (LillyDirect, checked 31 October 2026)
| Vial strength | Self-pay price per month | If not refilled within 45 days |
|---|---|---|
| 2.5 mg/0.5 mL (starting dosage) | Starting at $299 | No refill condition shown |
| 5 mg/0.5 mL | Starting at $399 | No refill condition shown |
| 7.5 mg/0.5 mL | Starting at $449 with a refill within 45 days | $499 |
| 10 mg/0.5 mL | Starting at $449 with a refill within 45 days | $699 |
| 12.5 mg/0.5 mL | Starting at $449 with a refill within 45 days | $699 |
| 15 mg/0.5 mL | Starting at $449 with a refill within 45 days | $699 |
Lilly defines a month as 28 days and 4 single-dose vials, requires a needle and syringe to be bought separately, and says the vial is available exclusively through LillyDirect self-pay, with free home delivery or free pickup at Walmart Pharmacy. The higher-dose prices reflect its Zepbound Journey Program, and Lilly notes that 2.5 mg is a starting dose, not a maintenance dose. These are Lilly's current prices on the day we read the pages, and they change. Our arithmetic on those prices: four 15 mg vials are 60 mg, so $449 works out to about $7.48 per milligram, and four 2.5 mg vials are 10 mg for $299, about $29.90 per milligram.
Research-labelled vials, Vendor Watch (read 31 October 2026)
These are list prices before any code, read from store pages by the Bureau's Vendor Watch on 31 October 2026 (07:30 UTC). Four of the 17 stores in that read returned a tirzepatide listing; the rest had none that day or could not be read. FDA's warning above applies to this category.
| Store | Listing | List price | Per mg |
|---|---|---|---|
| Luvaminos | 30 mg vial | $60.00 | $2.00 |
| PSPeptidesCheckout paused since 20 Nov 2026; the store says orders reopen soon. | 30 mg vial | $114.99 | $3.83 |
| Aurelia Research | 30 mg vial | $149.99 | $5.00 |
| PSPeptides | 10 mg vial | $54.99 | $5.50 |
| Aurelia Research | 10 mg vial | $69.99 | $7.00 |
| Costides | 20 mg, pack of 10 vials (in stock; its other pack sizes were out of stock) | $240.00 | $1.20 |
PSPeptides also listed 15 mg to 120 mg vials that day, up to $329.99 for 120 mg. A lower price per milligram does not make these products like for like: the vials carry no FDA review, and the Lilly prices include a labelled, FDA-approved dosage form. More on pricing is in the tirzepatide cost guide.
Compounded Tirzepatide Dosage: What the Zepbound Label Says
FDA does not approve compounded drugs, so there is no FDA-reviewed dose for them. The schedule below is the one on Lilly's FDA-approved Zepbound label (prescribing information revised 08/2026).
Calculate your draw for tirzepatide
Enter the vial strength, the bacteriostatic water you added and your dose, and get the exact mark on the syringe. Free, no signup, and the result comes with a link you can share or save.
Open the tirzepatide calculator peptulator.com, the Bureau's independent toolZepbound dose escalation, from the label
| Step | Weekly dose | What the label says |
|---|---|---|
| Start | 2.5 mg for 4 weeks | Treatment initiation; not approved as a maintenance dosage |
| After 4 weeks | 5 mg | A recommended maintenance dosage |
| Increase | 7.5 mg | Increases are in 2.5 mg steps, after at least 4 weeks on the current dose |
| Increase | 10 mg | A recommended maintenance dosage |
| Increase | 12.5 mg | A 2.5 mg step above 10 mg |
| Increase | 15 mg | Maximum recommended dosage; also a recommended maintenance dosage |
The label gives 5 mg, 10 mg or 15 mg once weekly as the maintenance dosage for weight reduction (10 mg or 15 mg for obstructive sleep apnea) and 15 mg once weekly as the maximum. It asks prescribers to consider response and tolerability when choosing a maintenance dosage. As covered above, FDA has reported adverse events that may be tied to compounded doses beyond the approved label, and dosing errors with compounded semaglutide from patients measuring doses wrongly; the calculator above shows the syringe mark for a given vial, water volume and dose. More on the schedule is in the tirzepatide dosage guide.
What the main trial covered
SURMOUNT-1 assigned 2,539 adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, to once-weekly tirzepatide or placebo for 72 weeks, including a 20-week dose-escalation period. It was supported by Eli Lilly and tested 5 mg, 10 mg and 15 mg doses. Its results are for that trial, not for any compounded or research-labelled vial.
- Mean change in body weight at week 72: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) and -3.1% on placebo.
- Weight reduction of 5% or more: 85%, 89% and 91% on 5 mg, 10 mg and 15 mg, against 35% on placebo.
- Weight reduction of 20% or more: 50% on 10 mg and 57% on 15 mg, against 3% on placebo.
- Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2% and 2.6% of participants on 5 mg, 10 mg, 15 mg and placebo.
What Research-Labelled Tirzepatide Is Typically Sold As
In the Bureau's Vendor Watch read of 31 October 2026, research-labelled tirzepatide was listed by total milligrams per vial, from 10 mg to 120 mg, and one store sold packs of ten vials. A listing gives the milligrams in the vial, not the concentration: if a vial is sold as a powder, the concentration depends on how much water is added, which the listing alone does not tell you. The peptide reconstitution guide covers the water arithmetic.
Sourcing Research-Grade Tirzepatide
Amino Club and PSPeptides both had tirzepatide vials in stock when the Bureau read their stores on 31 October 2026, each with a batch certificate of analysis on the product page. Research use only.
How to Evaluate a Research-Labelled Source
A certificate of analysis (COA) is the seller's document, not an FDA review, and FDA says unapproved versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed." If you still compare sellers, these are the Bureau's minimum checks:
- A COA from an independent laboratory, with purity by HPLC stated as a percentage and the method named.
- Identity confirmed by mass spectrometry. The Zepbound label gives tirzepatide's molecular weight as 4813.53 Da.
- A batch number on the COA that matches the vial you received, not one document reused across products.
- Specific storage and handling instructions. FDA's advice for multi-dose vials of compounded GLP-1s is to discard them 28 days after first use.
Passing these checks is not the same as a good independent record, which is worth reading where one exists. Certified Peptides carries accredited lab reports and a 62% Finnrick rating; Peptide Crafters has one of the most detailed lab pages we have read and a 60% rating; Onyx Research has certificates that match the lab's copies, on fills from 94% to 135% of label. We link those reviews as examples of how the two kinds of evidence differ, not as places to buy tirzepatide.
Side Effects and What the Label Shows
These are the Zepbound label's common adverse reactions in the two pooled placebo-controlled weight-reduction trials (percent of patients, label revised 08/2026). They are rates for Lilly's product; FDA says many of the events reported for compounded products appear consistent with those of the approved versions.
| Adverse reaction | Placebo (N=958) | 5 mg (N=630) | 10 mg (N=948) | 15 mg (N=941) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Injection site reactions | 2% | 6% | 8% | 8% |
Gastrointestinal reactions overall occurred in 56% of patients on each dose against 30% on placebo, and the label says most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. Stopping because of gastrointestinal reactions was 1.9% on 5 mg, 3.3% on 10 mg and 4.3% on 15 mg, against 0.5% on placebo. The label carries a boxed warning: in rats, tirzepatide causes thyroid C-cell tumors, and it is unknown whether it does in humans. The full breakdown is in the tirzepatide side effects guide.
Other GLP-1 Drugs and Compounding
FDA's page says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." It adds that they "are not components of FDA-approved drugs and have not been found safe and effective for any condition", and says it has warned telehealth companies marketing unapproved drugs such as retatrutide, API distributors selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities repackaging retatrutide. Semaglutide sits where tirzepatide does on the 503B lists, per the April 2026 notice. See also the Bureau's guides to compounded retatrutide and semaglutide versus tirzepatide.
Sourcing Tirzepatide for Research: What Matters
If you evaluate a research-labelled vial, the checks above are the minimum, and they do not make it an FDA-reviewed drug. Documentation changes by batch, so read the current COA on the seller's product page before ordering, and see the Bureau's vendor reviews for how each seller scores.
Research-Grade Tirzepatide with COA
Both vendors below publish a batch certificate of analysis on the product page. Research use only.
See also: survodutide.
Frequently Asked Questions
What is compounded tirzepatide?
Compounded tirzepatide is tirzepatide prepared by a pharmacy or outsourcing facility instead of Eli Lilly, the maker of Mounjaro and Zepbound. It is not FDA-approved. FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed.
Is compounded tirzepatide legal?
Only in narrow cases. FDA declared the tirzepatide shortage resolved on 19 December 2024, and the grace periods it gave compounders ended by 19 March 2025. Since then a pharmacy may not regularly compound essentially a copy of the approved drug unless a prescriber documents a significant difference for an identified patient, and FDA's April 2026 notice says tirzepatide is on neither the 503B bulks list nor the shortage list that outsourcing facilities need. FDA also says that, at this time, it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month.
Did a court uphold FDA's decision on compounded tirzepatide?
Yes. On 27 August 2026 the Fifth Circuit affirmed the judgment for FDA and Eli Lilly in Outsourcing Facilities Association v. FDA (No. 25-10600). It assumed without deciding that FDA should have used notice-and-comment rulemaking, held that the compounders had not shown prejudice from that, and found the shortage determination was not arbitrary or capricious. The opinion is not designated for publication.
Is compounded tirzepatide safe?
FDA cannot vouch for it, because it does not review compounded drugs for safety, effectiveness or quality before they are marketed. As of 31 May 2026 FDA had received more than 730 adverse event reports tied to compounded tirzepatide, and it says adverse events from compounded versions are likely underreported. FDA also reported dosing errors with compounded injectable semaglutide, from patients measuring incorrect doses and in some cases clinicians miscalculating them, and adverse event reports that may be tied to compounded semaglutide or tirzepatide doses beyond the approved label.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
It can contain the same active ingredient, but it is not the same product. Mounjaro and Zepbound are FDA-approved and went through FDA's review for safety, effectiveness and quality. Compounded versions are not approved, and FDA says compounded drugs are not the same as generic drugs. FDA has sent warning letters to telehealth companies over claims implying sameness with FDA-approved products.
How much does compounded tirzepatide cost?
We did not open a live compounding provider's price page on 31 October 2026, so we quote no compounded price. On that date Lilly's LillyDirect page listed Zepbound single-dose vials at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg with a refill within 45 days. Lilly lists $499 for 7.5 mg and $699 for the three higher strengths if a prescription is not refilled within 45 days, and a needle and syringe are bought separately. Research-labelled 30 mg tirzepatide vials in the Bureau's Vendor Watch data were listed at $60.00 to $149.99 that day, before any code.
What is the compounded tirzepatide dosage?
FDA does not approve compounded drugs, so there is no FDA-reviewed dose for them. The FDA-approved Zepbound label starts at 2.5 mg once weekly for 4 weeks, then 5 mg, with increases in 2.5 mg steps after at least 4 weeks on the current dose, and a maximum of 15 mg once weekly. FDA has received adverse event reports that may be related to compounded doses beyond what the approved label allows.
What has FDA said about telehealth companies selling compounded tirzepatide?
On 3 March 2026 FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products, citing claims that implied sameness with FDA-approved products and branding that implied the telehealth company is the compounder. FDA's guidance for telehealth companies, current as of 15 June 2026, also lists as misleading describing a compounded drug as a generic or as the same as an approved drug, and claiming it comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility, because FDA does not approve or license any facility.
Sources
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 1 October 2026; adverse event counts as of 31 May 2026): fda.gov. Checked 31 October 2026.
- FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of 1 April 2026; entries from 2 October 2024 to 1 April 2026): fda.gov. Checked 31 October 2026.
- FDA, Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound), 19 December 2024: fda.gov. Checked 31 October 2026.
- US Court of Appeals for the Fifth Circuit, Outsourcing Facilities Association v. FDA, No. 25-10600, opinion filed 27 August 2026 (not designated for publication): ca5.uscourts.gov. Checked 31 October 2026.
- FDA news release, FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, 3 March 2026: fda.gov. Checked 31 October 2026.
- FDA, FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs (content current as of 15 June 2026): fda.gov. Checked 31 October 2026.
- FDA warning letter to Sprout Health Partners LLC, 9 September 2025 (content current as of 16 September 2025): fda.gov. Checked 31 October 2026.
- Eli Lilly, Zepbound (tirzepatide) prescribing information, revised 08/2026: pi.lilly.com. Checked 31 October 2026.
- Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), N Engl J Med 2022;387(3):205-216, PMID 35658024, abstract: pubmed.ncbi.nlm.nih.gov. Checked 31 October 2026.
- LillyDirect, Zepbound page with KwikPen, vial and pen self-pay prices (vial section used): lilly.com. Checked 31 October 2026.
- Peptide Bureau Vendor Watch, tirzepatide store listings, list prices before any code, read 31 October 2026 (07:30 UTC). Bureau data, not an outside source.
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register notice 2026-22192, 91 FR 68526, 30 October 2026: federalregister.gov; policy text with Appendix A: hhs.gov. Checked 31 October 2026.
- Peptide Bureau, The FDA's Peptide "Interim Access Policy" Has Cleared White House Review, published 20 October 2026, updated 28 October 2026.
Legal and price details change; this page reflects the sources on the date shown. Educational content, not medical advice.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes